###begin article-title 0
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 446 454 446 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 459 466 459 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 332 337 <span type="species:ncbi:9606">human</span>
###xml 496 501 <span type="species:ncbi:10090">mouse</span>
###xml 503 506 <span type="species:ncbi:10116">rat</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
Microtubule-associated protein 2 (MAP2), a neuron-specific protein, stabilizes microtubules and is critical for neurite outgrowth and dendrite development. Although MAP2 is widely used as a marker of neuronal differentiation, regulation of its transcription has not been investigated. We showed that MAP2 is frequently activated in human cutaneous melanoma. Here, we identified a 2.2 kb region that is sufficient for neuronal-specific expression in vitro and in vivo. Comparative analysis of the mouse, rat and human MAP2 promoter sequences showed the presence of a conserved bHLH factor binding sites. Electrophoretic mobility shift analysis, promoter mutagenesis and co-transfection experiments showed that NeuroD, a pro-neuronal differentiation factor, and Hairy and Enhancer of Split (HES1), a transcription repressor, are involved in the regulation of MAP2 promoter activity. Melanoma cells express both NeuroD and HES1. Chromatin immunoprecipitation showed that in metastatic melanoma cells N-box region of the MAP2 promoter is occupied by endogenous HES1. We show that the inhibition of Notch signaling, a regulator of HES1 gene expression, and/or shRNA knockdown of HES1 results in the upregulation of MAP2 promoter activity. Thus, our data suggest that Notch signaling, which is implicated in melanoma progression, and HES1 play a role in MAP2 gene regulation during melanoma progression.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 605 606 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 607 608 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
Microtubule dynamics is regulated by a family of proteins known as microtubule-associated proteins (MAPs). MAP family includes several isoforms of MAP1, MAP2 and tau, which are expressed primarily in neurons. Among neuronal MAPs, MAP2 expression is considered a hallmark of neuronal differentiation (1,2). MAP2 is found primarily in the dendritic extensions of post-mitotic, terminally differentiated neurons. MAP2 plays a critical role in neurite outgrowth and dendrite development (3-5). Change in the expression of MAP2 is a helpful diagnostic and prognostic feature in various neurological disorders (6-8). Despite its extensive use as a marker of neuronal differentiation, and its role in morphological and functional differentiation of neurons, little is known about the regulation of MAP2 gene expression.
###end p 4
###begin p 5
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 953 961 953 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
Interestingly, MAP2 gene is activated in certain human non-neuronal cancers that exhibit characteristics of neural differentiation (2,9,10). We showed that cutaneous primary melanoma, a cancer that arises from neural crest-derived melanocytes, often express abundant MAP2 protein (11). Since the only function of MAP2, known to date, is to stabilize microtubules, we investigated whether MAP2 expression in rapidly proliferating cancer cells could interfere with microtubule dynamics, inhibit mitosis and, therefore, delay or inhibit tumor progression. We showed, in a five-year clinical follow-up study, that patients whose primary tumors express abundant MAP2 had longer disease-free survival rate than those patients with weak or no MAP2 expression (12). Moreover, we showed that reactivation of endogenous MAP2 gene transcription by treatment with pharmacological compounds or expression of exogenous MAP2 by adenovirus in metastatic melanoma cells in vitro leads to cell cycle arrest, growth inhibition and apoptosis (11,12). These observations suggested that reactivation of MAP2 gene transcription is potentially a useful strategy for the treatment of metastatic melanoma.
###end p 5
###begin p 6
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 277 284 277 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 58 63 <span type="species:ncbi:9606">human</span>
In this study, we show that a 3.3 kb 5' genomic region of human MAP2 gene that contains several E- and N-boxes, which are binding sites for basic helix-loop-helix (bHLH) transcription factors, is sufficient for neuronal-specific expression of a reporter gene both in vitro and in vivo. We also show that MAP2 promoter is activated by neurogenic bHLH factor NeuroD/BETA2, preferentially, in melanoma cells and repressed by the bHLH repressor Hairy and Enhancer of Split 1 (HES1), a regulator of neuronal differentiation. Although both NeuroD and HES1 are expressed in metastatic melanoma cells, results of co-transfection and chromatin immunoprecipitation experiments suggest that MAP2 gene is regulated by the relative levels of these factors, and predominantly by the level of HES1 protein. Using HES1shRNA knockdown and a pharmacological inhibitor of HES1 activator Notch1, we show that MAP2 promoter activity is regulated by Notch1. We also show that Notch1 signaling, which is implicated in melanoma progression (13-15), differentially regulates MAP2 promoter activity in primary and metastatic melanoma cells.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Cell culture
###end title 8
###begin p 9
###xml 655 656 655 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1006 1007 1006 1007 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1079 1080 1079 1080 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 265 268 <span type="species:ncbi:10116">rat</span>
###xml 372 377 <span type="species:ncbi:9606">human</span>
###xml 446 452 <span type="species:ncbi:9913">bovine</span>
###xml 462 467 <span type="species:ncbi:9606">Human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
###xml 910 916 <span type="species:ncbi:9913">bovine</span>
###xml 990 995 <span type="species:ncbi:9796">horse</span>
Mouse neuroblastoma cell line, Neuro2a, and human embryonal carcinoma cell line NT2-D1 were purchased from American Type Culture Collection (Manassas, VA). Neuro2a cells were grown in minimal essential medium (MEM). The human glioblastoma cell lines U251, U138 and rat PC12 cells were cultured in Rosewell Park Memorial Institute (RPMI) medium and DMEM, respectively. The human breast cancer cell line MCF-7 was cultured in MEM supplemented with bovine insulin. Human fibroblast cell line NIH3T3 was cultured in DMEM with high glucose, and human embryonic teratocarcinoma cell line NT2-D1 was cultured in DMEM with high glucose and supplemented with NaHCO3 (1.5 g/l). Neonatal foreskin melanocytes, primary melanoma cell lines WM35 and WM75, and metastatic melanoma cell lines SK-MEL-19, 451Lu and SK-MEL-23 cl.22a were cultured as described previously (16). All culture media were supplemented with 10% fetal bovine serum (FBS). Medium for PC12 cells were supplemented with 5% FBS and 10% horse serum, 1% l-glutamine, and 1% penicillin and streptomycin. All cell culture media, l-glutamine, penicillin and streptomycin, non-essential amino acids were from GIBCO (Grand Island, NY), and FBS was from Sigma (St Louis, MO) or Atlanta Biologicals (Lawrenceville, GA).
###end p 9
###begin title 10
Differentiation of PC12 cells
###end title 10
###begin p 11
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 47 52 <span type="species:ncbi:9796">horse</span>
Before differentiation, cells were grown in 1% horse serum containing media on collagen-coated tissue culture dishes. After the cells got attached, they were treated with 100 ng/ml nerve growth factor (NGF 2.5S; Promega, Madison, WI). Twenty-four hours after NGF treatment, cells were transfected with promoter constructs and cultured for additional 48 h in medium containing NGF. For MAP2 immunostaining, PC12 cells were treated with 100 ng/ml NGF for 6 days (17,18).
###end p 11
###begin title 12
Plasmids and antibodies
###end title 12
###begin p 13
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
###xml 163 169 <span type="species:ncbi:9986">Rabbit</span>
###xml 232 235 <span type="species:ncbi:10116">rat</span>
###xml 500 504 <span type="species:ncbi:9925">Goat</span>
###xml 902 913 <span type="species:ncbi:3704">Horseradish</span>
###xml 942 946 <span type="species:ncbi:9925">goat</span>
###xml 952 957 <span type="species:ncbi:10090">mouse</span>
###xml 1015 1020 <span type="species:ncbi:10090">mouse</span>
pCI-Hes1, a mouse Hes1 expression plasmid and Hes1 antibody (19) were gifts from Prof. R. Kageyama (Institute for Virus research, Kyoto University, Kyoto, Japan). Rabbit polyclonal antibody directed against the C-terminal region of rat Hes1 for supershift experiments was kindly provided by Dr Y. N. Jan (University of California, San Francisco, CA). NeuroD expression plasmid pCDNA3-NeuroD1-FLAG (pNeuroD) (20) was provided by Dr Haeyoung Suh-Kim (Ajou University School of Medicine, Suwon, Korea). Goat polyclonal anti-NeuroD antibody for western blot analysis (N-19) and for supershift experiments and chromatin immunoprecipitation assay (N-19X) and anti-HES1 antibody for ChIP (N-17X) were purchased from Santa Cruz Biotech (Santa Cruz, CA). Affinity purified anti-MAP2ab was obtained from Zymed Laboratories (San Francisco, CA), anti-alpha-tubulin antibody was obtained from Sigma (St Louis, MO). Horseradish peroxidase (HRP) conjugated goat anti-mouse IgG was from Jackson Laboratories (West Grove, PA). Anti-mouse IgG-FITC was purchased from Dako Corp. (Carpentaria, CA).
###end p 13
###begin title 14
###xml 16 21 <span type="species:ncbi:9606">human</span>
Construction of human MAP2 promoter-luciferase plasmids
###end title 14
###begin p 15
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MAP2 genomic sequence (GenBank accession no. NT_005403) was identified using BLAST search with MAP2 cDNA sequence, and a 2.2 kb region corresponding -1854 to +368 was amplified by PCR using forward primer 5'-CTGGCCTTTTTGGTTCTCAT and reverse primer 5'-TAGTCTAAGCTTAGC TGAGAATCTACCGA containing HindIII sites and subcloned into the HindIII site of pGL3 basic vector. This plasmid is designated as phMAP2-2. Since attempts to amplify the longer genomic DNA fragment containing region upstream of -1854 were unsuccessful, we first PCR amplified a region corresponding to -2965 to -106 using a forward primer 5'-GACGACAAGCTTCAGAAGAAGGGTAAGGCAAGCATCA and a reverse primer 5'-GACGACAAGCTTCGCAGTGGCGAACAGGAAAA, and constructed the longer phMAP2-1 plasmid by joining the 5' -2965/-263 fragment with -263/+369 fragment at the internal KpnI site. Deletion constructs phMAP2-3 (-263/+369) were made by splicing KpnI/KpnI (-1854/-268) fragment out from phMAP2-2 and re-ligating the plasmid. phMAP2-4 (-269/+30) was made by digestion of phMAP2-3 with PstI (+31) and HindIII (+368), followed by fill-in reaction with DNA polymerase (Klenow fragment) and blunt end ligation.
###end p 15
###begin title 16
E- and N-box mutant MAP2 promoters
###end title 16
###begin p 17
mutE1 (-2888/-2883), mutE2 (-2799/-2794), mutE3(-2304/-2299), mutE4 (-1593/-1588) individual mutations and various combination of E-box mutations (E1,2,3,4; E1,2,3; E2,3) were generated in phMAP2-1, mutN1 (-961/-956), mutN2 (-63/-58), mutE9 (-358/-353), mutE11 (-279/-274), mutE12 (+67/+72) and mutE13 (+267/+272) and combinations of these mutations (E12,13; E12,13,N1) were generated in phMAP2-2 using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. The following primers were used for mutagenesis (only sense sequence is given and mutated nucleotides within the consensus sequence are underlined):
###end p 17
###begin p 18
###xml 23 29 23 29 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACATGT</underline>
###xml 67 73 67 73 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCATGC</underline>
###xml 114 120 114 120 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTACAC</underline>
###xml 157 163 157 163 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTCTAC</underline>
###xml 202 208 202 208 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCGAGG</underline>
###xml 244 250 244 250 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCTTCC</underline>
###xml 285 291 285 291 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AATATT</underline>
###xml 330 336 330 336 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCTTGC</underline>
###xml 375 381 375 381 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACCAGA</underline>
###xml 420 426 420 426 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCCGCC</underline>
mutE1: 5'-CACAGAAGTATCTACATGTTCGGTTGTCTTG; mutE2: 5'-CTCCATGTTGGAAAGCATGCGGAAAAAAAGAAAAG; mutE3: 5'-GATGATGGTGGCAGGTACACTCTTTTAGACATC; mutE4: 5'-GGGAAAGAAAGTGTCTACGTGAGAGAAGAAAGG; mutE9: 5'-CACAAAGGAGACGCGAGGATGACATTCATAG; mutE11: 5'-GCCTGTCAGGGCTTCCGTACCAGAAG; mutE12: 5'-GTGGTATTGCTGAATATTCGCTGGTAATGG;mutE13: 5'-GAGTATAAAGAATGGGCTTGCCTTACTGGTGAG; mutN1: 5'-CACTTAACCTCCCTAACCAGAGGCACTGTAAAATAG; mutN2: 5'-GGCACACACAGAGCCGCCCTGGTGGCTTG CAG.
###end p 18
###begin title 19
Transient transfection and luciferase assays
###end title 19
###begin p 20
###xml 394 401 392 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 1113 1120 1107 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 1335 1342 1329 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
Transient transfections with various promoter constructs were performed using Lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Cells in 24- or 6-well tissue culture dishes, in triplicates, were transfected with 0.6 or 3 mug, respectively, of empty vector pGL3 or promoter-reporter constructs (phMAP2-1, phMAP2-2, phMAP2-3 and phMAP2-4) and 0.07 or 0.5 mug Renilla luciferase plasmid pRL. In co-transfection experiments, different amounts of NeuroD and Hes1 expression plasmids were added. For Notch1 inhibition and HES1 knockdown experiments, cells were either pre-treated with indicated amount of gamma-secretase inhibitor-DAPT (Calbiochem, La Jolla, CA) and/or transfected with indicated amount of lentiviral HES1shRNA plasmid (The RNAi Consortium collection, a library of short hairpin DNAs cloned in pLKO.1 lentiviral vector; Open biosystem, Huntsville, AL) 1 day before transfection with MAP2 promoter constructs. After 48 h of transfection, cells were washed with pre-chilled PBS and lysed in passive lysis buffer (Dual Luciferase kit, Promega). Firefly luciferase and Renilla luciferase activities in the cell lysates were measured according to the manufacturer's instructions using TD 20/20-luminometer (Turner Biosystems, Sunnyvale, CA). Firefly luciferase activity was normalized to the Renilla luciferase activity and reported as relative luciferase activity (RLA).
###end p 20
###begin title 21
Transient transgenic expression
###end title 21
###begin p 22
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 504 509 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 512 514 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
The 3.3 kb MAP2 genomic fragment from phMAP2-1 and 2.2 kb fragment from phMAP2-2 was isolated by digestion with HindIII and subcloned into the HindIII site upstream of Hsp68-lacZ gene in pHSF5 vector (21). The orientation and sequences were confirmed by restriction digestion and sequencing. Transgenic embryos were generated by Biotechnology Center (University of Wisconsin, Madison, WI). Embryos harvested on day 11.5 were stained for beta-galactosidase activity essentially as described by Shashikant et al. (21).
###end p 22
###begin title 23
Immunostaining
###end title 23
###begin p 24
###xml 286 288 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 307 312 <span type="species:ncbi:10090">mouse</span>
Control embryos (11.5 days old) were fixed in 4% formaldehyde overnight at 4degreesC and dehydrated using a graded series of methanol, and embedded in paraffin. Sections (9 mum thick) were cut and stained for MAP2 with anti-MAP2ab (Sigma) using citrate buffer antigen retrieval method (22) followed by anti-mouse IgG-HRP and the antigen was detected with HRP substrate diaminobenzidene.
###end p 24
###begin title 25
Electrophoresis mobility shift assay (EMSA)
###end title 25
###begin p 26
###xml 78 80 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 580 586 564 570 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACAAG</underline>
###xml 616 622 600 606 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAGAGG</underline>
###xml 649 655 633 639 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACGAG</underline>
###xml 687 693 671 677 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACCGGA</underline>
###xml 725 727 709 711 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AC</underline>
###xml 729 731 713 715 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AC</underline>
###xml 735 741 719 725 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACCGGA</underline>
###xml 772 778 756 762 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAACTG</underline>
###xml 785 791 769 775 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAGTTG</underline>
###xml 821 827 805 811 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACACGT</underline>
###xml 834 840 818 824 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACGTGT</underline>
###xml 867 873 851 857 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAAGTG</underline>
###xml 901 907 885 891 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACAGGT</underline>
###xml 934 940 918 924 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAGATG</underline>
###xml 968 974 952 958 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACGAGT</underline>
###xml 1002 1008 986 992 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACTTG</underline>
###xml 1038 1044 1022 1028 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACCTGT</underline>
###xml 1074 1080 1058 1064 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CATTTG</underline>
###xml 1117 1123 1101 1107 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCTTCC</underline>
###xml 1312 1314 1296 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
Wild type E- and N-boxes containing oligonucleotides were labeled with [gamma-32P]ATP (3000 Ci/mMol; ICN Biomedicals, Inc., Irvine, CA) with T4-polynucleotide kinase (Promega Corp., Madison, WI). Unincorporated label was removed using NAP5 columns (Amersham Pharmacia Biotech, Piscataway, NJ). Radioactivity in the eluted fractions was measured and approximately20 000 c.p.m were used for each binding reaction. The following reverse phase purified oligonucleotides were annealed and used as probes and competitors. Core sequences of E- and N-box are underlined: WtN1, 5'-CCTCCCTACACAAGGGCACTGT; mutN1, 5'-CCTCCCTAACCAGAGGCACTGT; WtN2, 5'-CACACACAGACACGAGCTGGTGGCTT; mutN2, 5'-CACACACAGAACCGGACTGGTGGCTT; mutN2-scrambled, 5'-ACCAACCAGAACCGGACTGGTGGCTT; WtE6E7, 5'-GGGATATTCAACTGCTAATTTCAGTTGCTAACATG; mutE6E7, 5'-GGGATATTACACGTCTAATTTACGTGTCTAACATG; WtE8, 5'-AACATGGCCAAGTGCATAATTA; mutE8, 5'-AACATGGCACAGGTCATAATTA; wtE9, 5'-AAGGAGACCAGATGATGACATT; mutE9, 5'-AAGGAGACACGAGTATGACATT; wtE10, 5'-TGGGGACACACTTGGATG GAGG; mutE10, 5'-TGGGGACAACCTGTGATGGAGG; wtE11, 5'-GCCTGTCAGGCATTTGGTACCAGAAG; and mutE11, 5'-GCCTGTCAGGGCTTCCGTACCAGAAG. Nuclear extracts of COS-7 or cl.22a melanoma cells transfected with Hes1 expression plasmid or with NeuroD expression plasmid were prepared essentially as described previously (16). Labeled probes were incubated with 5-10 mug of nuclear extract at room temperature for 30 min. For supershift experiments, anti-Hes1 or anti-NeuroD antibody or unrelated polyclonal antibody were added to the reaction mixture and incubated at room temperature for additional 30 min. DNA-protein complexes were analyzed by electrophoresis on non-denaturing 5% polyacrylamide gels run at constant 200 V for 2 h in 0.5x TBE. The gels were dried and exposed to X-ray film (Eastman Kodak Company, Rochester, NY).
###end p 26
###begin title 27
Chromatin immunoprecipitation assay (ChIP assay)
###end title 27
###begin p 28
Assay was performed using ChIP-IT kit (Active Motif, Carlsbad, CA) following the manufacturer's protocol. Briefly, SK-MEL-23 cells were cross linked, chromatin was prepared and immunoprecipitated with anti-HES1 antibody (Santa Cruz) or with control IgG. Then, immunoprecipitated DNA was eluted and PCR amplified using appropriate primers. For PCR amplification of N1 (36 cycles) and N2 (29 cycles) box region in MAP2 promoter region, the following primers were used: N1-forward, 5'-CCCAGGAAATAAATGCAGGA; N1-reverse, 5'-GGGCCGATATGTGATTTCTG; N2-forward, 5'-CCACTCGCCTTATTTTCCTG; and N2-reverse, 5'-CGCATATGCAGCAAACAC. For PCR amplification of E9-E11 boxes (36 cycles) in promoter region the following primers were used: forward, 5'-TAAGCGGTGTGTGTGTGTGC; and reverse, 5'-ATGATGACAAGCCACTCAGC.
###end p 28
###begin title 29
RT-PCR
###end title 29
###begin p 30
Total RNA was isolated from different melanoma and non-melanoma cells using RNeasy Mini Kit (Qiagen, Valencia, CA) and amplified by using one-step RT-PCR Kit (Qiagen) as per manufacturer's instructions using 100 ng of total RNA and MAP2 forward primer 5'-GCAGTTCTCAAAGGCTAGAC (nt 31-50 in MAP2ab cDNA in exon 3) and reverse primer 5'-TTGATCGTGGAACTCCATCT (nt 721-740 in MAP2ab cDNA in exon 9).
###end p 30
###begin title 31
SDS-PAGE and western blotting
###end title 31
###begin p 32
Total cell lysates of normal melanocytes, different melanoma and non-melanoma cell lines were prepared using lysis buffer [1% Triton X-100 in PBS containing cocktail of protease inhibitors (Roche Diagnostics Corp., Indianapolis, IN)]. Protein was estimated using BCA protein assay kit (Pierce Biotechnology Inc., Rockford, IL) and 50-100 mug protein was separated on 9% SDS-PAGE, transferred on to Polyscreen membrane (NEN Life Sciences, Boston, MA) and the membranes were blocked and then incubated overnight at 4degreesC with the primary antibodies diluted (anti-Hes1 at 0.6 mug/ml; anti-NeuroD at 1:250; anti-alpha-tubulin at 1:2000 and anti-beta-actin at 1:2000) in 5% non-fat dry milk in TBST, followed by incubation with the appropriate HRP-conjugated secondary antibodies (at 1:5000 to 1:10 000 dilution) for 1 h at room temperature. Protein bands were detected by chemiluminescence using ECL kit (Amersham Biosciences, Piscataway, NJ).
###end p 32
###begin title 33
RESULTS
###end title 33
###begin title 34
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
###xml 67 70 <span type="species:ncbi:10116">rat</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
Nucleotide sequences upstream of MAP2 gene are conserved in mouse, rat and human
###end title 34
###begin p 35
###xml 632 647 632 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A and B</xref>
###xml 686 1058 686 1058 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="36">Mouse, rat (GenBank accession nos: mouse, NT_039170; and rat, NW_047816) and human MAP2 genomic sequences show 80% sequence identity in 1 kb region corresponding to &#8722;691/+365 of human MAP2 genomic sequence. In addition, an 87 bp rat genomic sequence showed 85% identity to human sequences between &#8722;1388/&#8722;1302. There were no homologous sequences to this 87 bp in the mouse.</p>
###xml 686 1058 686 1058 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="36">Mouse, rat (GenBank accession nos: mouse, NT_039170; and rat, NW_047816) and human MAP2 genomic sequences show 80% sequence identity in 1 kb region corresponding to &#8722;691/+365 of human MAP2 genomic sequence. In addition, an 87 bp rat genomic sequence showed 85% identity to human sequences between &#8722;1388/&#8722;1302. There were no homologous sequences to this 87 bp in the mouse.</p></list-item>
###xml 1336 1338 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 1339 1341 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 1058 1343 1058 1343 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="37">Inspection of the 3.3 kb human MAP2 5&#8242; genomic sequence showed the presence of 13 (E1&#8211;E13) putative E boxes (CANNTG) and two (N1 and N2) putative N-boxes (CACNAG), which are potential sites for binding bHLH proteins including neuronal transcriptional activators and repressors (<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p>
###xml 1058 1343 1058 1343 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="37">Inspection of the 3.3 kb human MAP2 5&#8242; genomic sequence showed the presence of 13 (E1&#8211;E13) putative E boxes (CANNTG) and two (N1 and N2) putative N-boxes (CACNAG), which are potential sites for binding bHLH proteins including neuronal transcriptional activators and repressors (<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p></list-item>
###xml 1343 1775 1343 1775 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="38">The proximal cluster of three E boxes (E9&#8211;E11) at &#8722;358/&#8722;353, &#8722;313/&#8722;308 and &#8722;279/&#8722;274, and a N2 box &#8722;63/&#8722;58 found in the human MAP2 sequence are conserved among mouse, rat and human sequences; additional upstream (E1&#8211;E8) and downstream (E12 and E13 within exon 1 and at +267/+272 within intron 1) E boxes and N1 box at &#8722;961/&#8722;956 within the human MAP2 promoter sequence are not present in the mouse and the rat MAP2 genomic sequences.</p>
###xml 1343 1775 1343 1775 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="38">The proximal cluster of three E boxes (E9&#8211;E11) at &#8722;358/&#8722;353, &#8722;313/&#8722;308 and &#8722;279/&#8722;274, and a N2 box &#8722;63/&#8722;58 found in the human MAP2 sequence are conserved among mouse, rat and human sequences; additional upstream (E1&#8211;E8) and downstream (E12 and E13 within exon 1 and at +267/+272 within intron 1) E boxes and N1 box at &#8722;961/&#8722;956 within the human MAP2 promoter sequence are not present in the mouse and the rat MAP2 genomic sequences.</p></list-item>
###xml 1915 1917 1915 1917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1918 1920 1918 1920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1921 1923 1921 1923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 1775 1925 1775 1925 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="39">No canonical TATA box could be identified in the MAP2 proximal 5&#8242; genomic sequences, suggesting that MAP2 promoter is a TATA-less promoter (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b25">25</xref>,<xref ref-type="bibr" rid="b26">26</xref>).</p>
###xml 1775 1925 1775 1925 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="39">No canonical TATA box could be identified in the MAP2 proximal 5&#8242; genomic sequences, suggesting that MAP2 promoter is a TATA-less promoter (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b25">25</xref>,<xref ref-type="bibr" rid="b26">26</xref>).</p></list-item>
###xml 686 1925 686 1925 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="roman-lower"><list-item><p textid="36">Mouse, rat (GenBank accession nos: mouse, NT_039170; and rat, NW_047816) and human MAP2 genomic sequences show 80% sequence identity in 1 kb region corresponding to &#8722;691/+365 of human MAP2 genomic sequence. In addition, an 87 bp rat genomic sequence showed 85% identity to human sequences between &#8722;1388/&#8722;1302. There were no homologous sequences to this 87 bp in the mouse.</p></list-item><list-item><p textid="37">Inspection of the 3.3 kb human MAP2 5&#8242; genomic sequence showed the presence of 13 (E1&#8211;E13) putative E boxes (CANNTG) and two (N1 and N2) putative N-boxes (CACNAG), which are potential sites for binding bHLH proteins including neuronal transcriptional activators and repressors (<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p></list-item><list-item><p textid="38">The proximal cluster of three E boxes (E9&#8211;E11) at &#8722;358/&#8722;353, &#8722;313/&#8722;308 and &#8722;279/&#8722;274, and a N2 box &#8722;63/&#8722;58 found in the human MAP2 sequence are conserved among mouse, rat and human sequences; additional upstream (E1&#8211;E8) and downstream (E12 and E13 within exon 1 and at +267/+272 within intron 1) E boxes and N1 box at &#8722;961/&#8722;956 within the human MAP2 promoter sequence are not present in the mouse and the rat MAP2 genomic sequences.</p></list-item><list-item><p textid="39">No canonical TATA box could be identified in the MAP2 proximal 5&#8242; genomic sequences, suggesting that MAP2 promoter is a TATA-less promoter (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b25">25</xref>,<xref ref-type="bibr" rid="b26">26</xref>).</p></list-item></list>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
###xml 571 576 <span type="species:ncbi:10090">mouse</span>
###xml 581 584 <span type="species:ncbi:10116">rat</span>
###xml 686 691 <span type="species:ncbi:10090">Mouse</span>
###xml 693 696 <span type="species:ncbi:10116">rat</span>
###xml 721 726 <span type="species:ncbi:10090">mouse</span>
###xml 743 746 <span type="species:ncbi:10116">rat</span>
###xml 763 768 <span type="species:ncbi:9606">human</span>
###xml 864 869 <span type="species:ncbi:9606">human</span>
###xml 915 918 <span type="species:ncbi:10116">rat</span>
###xml 959 964 <span type="species:ncbi:9606">human</span>
###xml 1052 1057 <span type="species:ncbi:10090">mouse</span>
###xml 1083 1088 <span type="species:ncbi:9606">human</span>
###xml 1463 1468 <span type="species:ncbi:9606">human</span>
###xml 1503 1508 <span type="species:ncbi:10090">mouse</span>
###xml 1510 1513 <span type="species:ncbi:10116">rat</span>
###xml 1518 1523 <span type="species:ncbi:9606">human</span>
###xml 1682 1687 <span type="species:ncbi:9606">human</span>
###xml 1734 1739 <span type="species:ncbi:10090">mouse</span>
###xml 1748 1751 <span type="species:ncbi:10116">rat</span>
Using BLAST search, we identified the human genomic sequences upstream of MAP2 cDNA in a chromosome 2 contig (GenBank accession no. NT_005403) and amplified, by PCR, a 3334 bp genomic DNA fragment consisting 2965 nt upstream of MAP2 transcription start site (+1), exon 1 (78 bp) and a part of intron 1 (291 bp). We sequenced this fragment (GenBank accession no. DQ 386449), and cloned it into pGL3 luciferase reporter vector (phMAP2-1; -2965/+369). First, we analyzed this MAP2 genomic sequence for transcription factor binding sites and compared the human sequence with mouse and rat MAP2 genomic sequences using CLUSTALW program (Figure 1A and B). This analysis showed the following: Mouse, rat (GenBank accession nos: mouse, NT_039170; and rat, NW_047816) and human MAP2 genomic sequences show 80% sequence identity in 1 kb region corresponding to -691/+365 of human MAP2 genomic sequence. In addition, an 87 bp rat genomic sequence showed 85% identity to human sequences between -1388/-1302. There were no homologous sequences to this 87 bp in the mouse.Inspection of the 3.3 kb human MAP2 5' genomic sequence showed the presence of 13 (E1-E13) putative E boxes (CANNTG) and two (N1 and N2) putative N-boxes (CACNAG), which are potential sites for binding bHLH proteins including neuronal transcriptional activators and repressors (23,24).The proximal cluster of three E boxes (E9-E11) at -358/-353, -313/-308 and -279/-274, and a N2 box -63/-58 found in the human MAP2 sequence are conserved among mouse, rat and human sequences; additional upstream (E1-E8) and downstream (E12 and E13 within exon 1 and at +267/+272 within intron 1) E boxes and N1 box at -961/-956 within the human MAP2 promoter sequence are not present in the mouse and the rat MAP2 genomic sequences.No canonical TATA box could be identified in the MAP2 proximal 5' genomic sequences, suggesting that MAP2 promoter is a TATA-less promoter (20,25,26).
###end p 35
###begin p 36
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 7 10 <span type="species:ncbi:10116">rat</span>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
###xml 57 60 <span type="species:ncbi:10116">rat</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
###xml 229 232 <span type="species:ncbi:10116">rat</span>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 366 371 <span type="species:ncbi:10090">mouse</span>
Mouse, rat (GenBank accession nos: mouse, NT_039170; and rat, NW_047816) and human MAP2 genomic sequences show 80% sequence identity in 1 kb region corresponding to -691/+365 of human MAP2 genomic sequence. In addition, an 87 bp rat genomic sequence showed 85% identity to human sequences between -1388/-1302. There were no homologous sequences to this 87 bp in the mouse.
###end p 36
###begin p 37
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Inspection of the 3.3 kb human MAP2 5' genomic sequence showed the presence of 13 (E1-E13) putative E boxes (CANNTG) and two (N1 and N2) putative N-boxes (CACNAG), which are potential sites for binding bHLH proteins including neuronal transcriptional activators and repressors (23,24).
###end p 37
###begin p 38
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 160 165 <span type="species:ncbi:10090">mouse</span>
###xml 167 170 <span type="species:ncbi:10116">rat</span>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 339 344 <span type="species:ncbi:9606">human</span>
###xml 391 396 <span type="species:ncbi:10090">mouse</span>
###xml 405 408 <span type="species:ncbi:10116">rat</span>
The proximal cluster of three E boxes (E9-E11) at -358/-353, -313/-308 and -279/-274, and a N2 box -63/-58 found in the human MAP2 sequence are conserved among mouse, rat and human sequences; additional upstream (E1-E8) and downstream (E12 and E13 within exon 1 and at +267/+272 within intron 1) E boxes and N1 box at -961/-956 within the human MAP2 promoter sequence are not present in the mouse and the rat MAP2 genomic sequences.
###end p 38
###begin p 39
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
No canonical TATA box could be identified in the MAP2 proximal 5' genomic sequences, suggesting that MAP2 promoter is a TATA-less promoter (20,25,26).
###end p 39
###begin title 40
MAP2 promoter activity
###end title 40
###begin p 41
###xml 603 612 603 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 932 941 932 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 368 371 <span type="species:ncbi:10116">rat</span>
###xml 387 392 <span type="species:ncbi:9606">human</span>
To investigate the promoter activity of MAP2 5' genomic sequence, we generated, in addition to the 3.3 kb luciferase reporter plasmid (phMAP2-1), 5' deletion constructs phMAP2-2 (-1864/+369), phMAP2-3 (-263/+369) and a 3' deletion construct phMAP2-4 (-263/+30) that lacks intron 1 sequence and part of exon 1. We tested the activity of these MAP2 promoter plasmids in rat PC12 cells and human teratocarcinoma cell line NT2/D1 by transient transfection followed by luciferase assays. PC12 cells treated with NGF are known to differentiate into neuron-like cells with neurite outgrowths and express MAP2 (Figure 2A, inset) (17,18). NT2/D1 is an inducible model system for neuronal differentiation. Continuous culture of NT2/D1 cells in complete serum containing retinoids or the addition of retinoic acid to the steroid free culture medium is known to induce neuronal differentiation and MAP2 expression (as shown by RT-PCR, inset in Figure 2B) in these cells (27).
###end p 41
###begin p 42
###xml 632 641 620 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 1495 1500 <span type="species:ncbi:9606">human</span>
In NGF-treated PC12 cells, phMAP2-1 and phMAP2-2 promoter constructs showed 6- to 7-fold higher luciferase activity compared with untreated cells. Although promoter construct lacking sequences between -1854/-263 (phMAP2-3) showed approximately2-fold higher basal activity compared with phMAP2-1 and phMAP2-2 in untreated PC12 cells, NGF treatment did not produce a significant increase in the luciferase activity. In non-neuronal HeLa cells, all three promoter constructs produced only weak luciferase activity and treatment with NGF produced a 2-fold increase only in cells transfected with the 3.3 kb phMAP2-1 promoter construct (Figure 2A). We found that luciferase activity driven by the 3.3 kb MAP2-1 promoter was always lower than that of the shorter 2.2 kb MAP2-2 promoter fragment in every cell line tested, indicating the presence of negative regulatory sequences between nt -2965 and -1854. There are four putative E boxes (E1-E4) within this region of MAP2 DNA. To test whether these E boxes play a role in attenuating MAP2 promoter activity, we mutated E1, E2, E3 and E4 boxes individually or in various combinations including mutation of all four E boxes and tested the activity of the mutant promoters. Mutation of neither individual E boxes nor any combination of E boxes (including all four E boxes) altered the basal activity of the 3.3 kb phMAP2-1 promoter (data not shown). These data suggested that the distal E boxes do not contribute significantly to the basal activity of human MAP2 promoter and showed that the 2.2 kb genomic fragment -1854/+369 (phMAP2-2) was sufficient for maximal NGF-inducible, neuronal-selective MAP2 promoter activity.
###end p 42
###begin p 43
###xml 306 315 306 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
###xml 740 749 740 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2C</xref>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 1343 1345 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 510 515 <span type="species:ncbi:9606">human</span>
In NT2 cells cultured in complete medium, phMAP2-2 produced 150- to 200-fold higher luciferase activity compared with the promoter-less pGL3-luc plasmid. Luciferase activity in transfected NT2 cells was 15- to 20-fold higher than that found in HeLa cells transfected with the same MAP2 promoter construct (Figure 2B) confirming the neuronal-specificity of the 2.2 kb MAP2 promoter. We then tested the activity of this MAP2 promoter in a representative panel of primary and metastatic melanoma cells lines, and human glioblastoma cell lines U138, U251 and a breast cancer cell line, MCF-7. In phMAP2-2 transfected melanoma cells, there was 20- to 30-fold higher luciferase activity compared to cells transfected with promoter-less pGL3-Luc (Figure 2C). Surprisingly, both primary and metastatic melanoma cells showed significant MAP2 promoter activity. Although MAP2 promoter activity in melanoma cells was lower than that found in NT2 cells, it was 4- to 6-fold higher than that observed in HeLa cells or MCF-7 cells (data not shown). MAP2 promoter activity was comparable to the activity in glioblastoma cell lines (data not shown). These data show that the neuronal-specific MAP2 gene promoter is active in melanoma cells and are consistent with the well-documented molecular plasticity and neural differentiation of cutaneous melanomas (28,29).
###end p 43
###begin title 44
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
MAP2 promoter activity in vivo
###end title 44
###begin p 45
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 275 277 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 850 859 844 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A</xref>
###xml 1223 1238 1214 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A and B</xref>
###xml 1361 1368 1352 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
###xml 1153 1158 <span type="species:ncbi:9606">human</span>
###xml 1273 1278 <span type="species:ncbi:9606">human</span>
To verify that the cloned MAP2 genomic DNA fragments show neuronal-specific expression in vivo, we tested their activity by transient expression in transgenic mouse embryos. Promoter fragments hMAP2-1 and hMAP2-2 were cloned into beta-galactosidase reporter construct pHHSF (21) and transgenic embryos were generated. Two independent sets of transgenic embryos were created for each construct. Staining of 11.5-day-old embryos with X-gal showed beta-galactosidase activity in 6 of 11 and 8 of 25 embryos produced by microinjection of hMAP2-1 and hMAP2-2, respectively. The X-gal staining was restricted to developing central nervous system including a weak staining of telencephalic vesicle and strong staining of ventral mesencephalon, midbrain and hindbrain junction (isthmus), rhombic lip and along the length of the neural tube, developing eyes (Figure 3A). Both hMAP2-1 and hMAP2-2 transgenic embryos showed similar pattern of staining. Staining of sections of paraffin embedded, 11.5-day-old littermate control embryos with anti-MAP2ab-specific mAb M13 showed expression of endogenous MAP2 protein in the same regions corresponding to those where human MAP2 promoter driven beta-galactosidase activity was expressed (Figure 3A and B). These data show that the 2.2 kb human MAP2 promoter also contains sequences necessary for neuronal-selective expression in vivo.
###end p 45
###begin title 46
Regulation of MAP2 promoter
###end title 46
###begin p 47
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
Since MAP2 is a marker of neuronal differentiation, we investigated the possibility that MAP2 promoter is regulated by the key neuronal transcription factors. NeuroD/BETA2 is a critical bHLH neurogenic factor that binds to a core 6 bp E box element (CANNTG) as a heterodimer with a ubiquitous partner E47 (30). HES1 is an important negative regulator of neurogenesis (24). HES1 represses neuronal genes actively by binding to N-box (CACNTG) as a homodimer or in a dominant-negative fashion by forming heterodimers with other bHLH factors that bind to E boxes (24,31).
###end p 47
###begin p 48
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
A role of NeuroD in the regulation of MAP2 gene promoter is indicated by the following observations: (i) in neuroepithelial cells, induction of cell cycle arrest and neuronal differentiation is associated with the activation of NeuroD and MAP2 expression (32). (ii) MAP2 promoter contains a consensus NeuroD-binding E-box (CAGATG) found in other NeuroD target gene (33).
###end p 48
###begin p 49
###xml 215 224 215 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 664 673 664 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
To test whether NeuroD activates MAP2 promoter, we transfected HeLa cells and melanoma cells with MAP2 promoter plasmids phMAP2-1 or phMAP2-2 and increasing amounts of NeuroD expression plasmid pNeuroD. As shown in Figure 4A, co-transfection with pNeuroD produced a dose-dependent increase in luciferase activity in both phMAP2-1 and phMAP2-2 promoter transfected melanoma cells. In HeLa cells, co-transfection of pNeuroD appears to suppress the MAP2 promoter activity at lower dose but stimulates it slightly at a higher dose. However, NeuroD-stimulated MAP2 promoter activity in HeLa cells was significantly lower than its basal activity seen in melanoma cells (Figure 4A).
###end p 49
###begin p 50
###xml 304 306 304 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 424 433 424 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 676 685 676 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Since the consensus NeuroD-binding E-box, E9 is conserved between human and rodent MAP2, we first tested binding of NeuroD to E9 box sequences by electrophoretic mobility gel shift assay. Incubation of nuclear extracts of pNeuroD transfected (to enhance the sensitivity of the assay) melanoma cells with 32P-labeled oligonucleotides (22mers with a core E-box sequence CANNTG) showed that the oligomer containing the E9 box (Figure 4B, lane 1), but not E10 or E11 box (data not shown), produce two DNA-protein complexes. Appearance of these complexes, especially the slower migrating complex, was inhibited in the presence of molar excess of wild-type cold E9 oligonucleotide (Figure 4B, lanes 2 and 3). Addition of molar excess of mutant E9 oligonucleotide with a core sequence ACGAGT (lanes 4 and 5) or wild-type E10 oligonucleotide (lanes 6 and 7) produced only a slight inhibition in the formation of slow migrating E9-protein complex. Addition of anti-NeuroD antibody (lane 9) to the reaction mixture completely prevented the formation of these complexes, similar to the reported effect of this antibody on binding of NeuroD to E boxes of other target genes (34,35). These data show that NeuroD binds to E9 box (-366/-345) of MAP2 promoter.
###end p 50
###begin p 51
###xml 658 667 658 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5A</xref>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 1037 1039 1035 1037 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GC</underline>
###xml 1041 1042 1039 1040 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 1127 1136 1125 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5B</xref>
###xml 1330 1339 1328 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
We observed that a MAP2 promoter deletion construct of pMAP2-3 (-263/+369) that lacks all proximal E boxes, including E9, still produced significant luciferase activity that was less than the maximal activity seen in cells transfected with the 2.2 kb phMAP2-2 promoter plasmid. To test whether this promoter constructs lacking the proximal E boxes could still be activated by NeuroD, we transfected HeLa cells and melanoma cells with phMAP2-3 plasmid and with increasing amounts of pNeuroD. Surprisingly, co-transfection with pNeuroD resulted in a dose-dependent increase in luciferase activity of this MAP2 promoter in melanoma cells but not in HeLa cells (Figure 5A). These data suggest that although NeuroD can activate MAP2 gene transcription by binding to E9 box, other factors that are constitutively expressed in melanoma cells and those that may be activated by NeuroD contribute to the transactivation of MAP2 promoter. To test this, we generated 2.2 kb phMAP2-2 promoter with mutations in the core sequence of E9 box (CAGATG-->GCGAGG), and compared its basal activity with that of the wild-type promoter. As shown in Figure 5B, mutation of E9 box resulted in nearly 50% decrease in the basal luciferase activity. Additionally, this E9 mutant phMAP2-2 promoter continued to exhibit a dose-dependent activation by NeuroD (Figure 5C). Thus, NeuroD appears to upregulate MAP2 promoter activity by both direct (by binding to E9 box) and indirect mechanisms (presumably by activation or induction of other trans-activators).
###end p 51
###begin title 52
MAP2 promoter is inhibited by HES1
###end title 52
###begin p 53
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 620 629 620 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6A</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 363 368 <span type="species:ncbi:10090">mouse</span>
As mentioned earlier, HES1 is an important regulator of neurogenesis and neuronal differentiation, Hes1 null mice express both early and late neuronal markers including MAP2 prematurely (36). To test whether MAP2 promoter is regulated by HES1, we co-transfected NT2 cells and melanoma cells (SK-MEL-19) with the 2.2 kb phMAP2-2 promoter and increasing amounts of mouse Hes1 expression plasmid pCI-Hes1. In both NT2 cells (data not shown) and melanoma cells, co-transfection with Hes1 resulted in a dose-dependent inhibition of luciferase activity with a maximal (84%) inhibition at the highest dose of pCI-Hes1 plasmid (Figure 6A). These data suggest a role for HES1 in the regulation of MAP2 promoter activity.
###end p 53
###begin title 54
The proximal N-box is necessary for HES1-mediated repression
###end title 54
###begin p 55
###xml 610 611 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 734 743 730 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6B</xref>
###xml 972 981 968 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6C</xref>
###xml 983 984 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 996 997 992 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1292 1294 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 1691 1700 1687 1696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6D</xref>
In phMAP2-2 promoter sequence, there are two putative HES-binding motifs: N1 at -961/-956 (CACAAG) and N2 at -63/-58 (CACGAG). To investigate the role of these N-boxes in repression of MAP2 promoter activity by HES1, we tested whether mutation of either one or both N-boxes increases basal activity of the promoter and/or makes it less sensitive or refractory to repression by HES1. In melanoma cells transfected with the mutant phMAP2-2 promoter plasmids, there was a modest but significant increase (26% over wild type) in the luciferase activity driven by the mutN2 (CACGAG-->GCCGCC) and mutN1N2 promoters (P < 0.05), and a smaller increase (10% over wild type) in the activity driven by the mutN1 (CACAAG-->ACCAGA) MAP2 promoter (Figure 6B). In addition, co-transfection with pCI-Hes1, which resulted in 60% inhibition of luciferase activity driven by the wild-type and mutN1 promoters, produced significantly less inhibition of mutN2 and mutN1N2 promoter activities (Figure 6C, P < 0.05 and P < 0.01, respectively). These data suggest that N2 box is involved in HES1-mediated repression of MAP2 promoter. In addition to its action by direct binding to N2 box, HES1 is also known to act indirectly by making non-functional heterodimers with transcription activators that bind to E boxes (37). Whereas the 2.2 kb MAP2 minimal promoter contains two potential HES-binding N-boxes, the 293 bp phMAP2-4 promoter deletion construct that we generated contains only the proximal N2 box. Transfection of melanoma cells with phMAP2-4 promoter-luciferase plasmid and Hes1 expression plasmid showed that Hes1 was able to repress the activity of phMAP2-4 promoter containing only the proximal N-box (Figure 6D), confirming that the regulation of MAP2 promoter by HES1 is mediated primarily by this proximal N2 box at -63/-58.
###end p 55
###begin p 56
###xml 106 115 106 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6E</xref>
###xml 452 461 452 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6E</xref>
###xml 734 743 734 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6E</xref>
###xml 994 1003 994 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6E</xref>
###xml 798 804 <span type="species:ncbi:9986">rabbit</span>
To test whether HES1 binds to N2 sequence, we performed electrophoretic mobility shift assay. As shown in Figure 6E, Hes1 transfected melanoma nuclear extracts retarded the mobility of N2 box oligonucleotides. Addition of a molar excess of cold wild-type N2 box DNA resulted in a complete inhibition of the mobility shift of the labeled N2 box oligonucleotide. In some experiments, we also observed a second, faster migrating and non-specific complex (Figure 6E, asterisk on the left), which could not be competed out by molar excess of cold N2 box DNA. The presence of molar excess wild-type N1 box or mutant N2 box oligonucleotides in the reaction resulted in only a slight decrease in the formation of this N2 DNA-protein complex (Figure 6E). The addition of anti-Hes1 antibody, but not control rabbit IgG, to the reaction caused further retardation of the N2 box-protein complex. However, addition of these antibodies to N2 DNA-protein complex showed two additional non-specific complexes (Figure 6E, asterisks on the right). These data showed that HES1 represses MAP2 promoter activity by binding preferentially to the proximal N2 box sequence.
###end p 56
###begin title 57
HES1 is a dominant regulator of MAP2 promoter activity
###end title 57
###begin p 58
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 989 998 977 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7A</xref>
###xml 1203 1212 1191 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7B</xref>
###xml 1297 1302 <span type="species:ncbi:9606">human</span>
Neuronal differentiation is known to be regulated by the relative levels of pro-neuronal transcription factors and repressors neuronal-specific genes (38). To investigate the relative contribution of NeuroD and HES1 in the regulation of MAP2 promoter activity, we co-transfected melanoma cells with phMAP2-2 and (i) constant amount of NeuroD expression plasmid and increasing amounts of pCI-Hes1 plasmid or (ii) a constant amount of pCI-Hes1 plasmid and increasing amounts of pNeuroD plasmid. In melanoma cells, co-transfection with pNeuroD alone resulted in approximately50% increase in luciferase activity driven by phMAP2-2 promoter, and transfection of the promoter with pCI-Hes1 resulted in 60% inhibition in promoter activity. Transfection with increasing amounts of pCI-Hes1 along with constant amount of pNeuroD that produces 50% increase in promoter activity, not only prevented the pNeuroD-dependent increase but also produced a dose-dependent decrease in the promoter activity (Figure 7A). In contrast, co-transfection of increasing amounts of pNeuroD, which upregulated MAP2 promoter activity when present alone, was unable to relieve the inhibition of the promoter activity caused by HES1 (Figure 7B). These data suggest that HES1 is a dominant regulator of MAP2 promoter activity in human melanoma cells.
###end p 58
###begin p 59
###xml 297 306 297 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7C</xref>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
To test whether melanoma cells express these neuronal transcription factors and whether variable MAP2 promoter activity in different melanoma cell lines might be related to relative levels of these factors, we performed western blot analysis with anti-NeuroD and anti-Hes1 antibodies. As shown in Figure 7C, whereas variable amounts of NeuroD expression could be detected in both melanocytes and melanoma cells, HES1 expression is detectable only in melanoma cells. These observations support the RT-PCR data reported by Balint et al. (39), who showed that HES family mRNAs (specifically HES1) are expressed in melanoma cell lines but not in melanocytes. There was no clear relationship between the levels of NeuroD and HES1 among different melanoma cell lines.
###end p 59
###begin p 60
###xml 153 162 153 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7D</xref>
###xml 386 395 386 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7D</xref>
To test whether endogenous NeuroD and HES1 proteins in melanoma cells bind to MAP2 promoter sequence, we performed chromatin immunoprecipitation assays (Figure 7D). Sheared chromatin was immunoprecipitated with anti-NeuroD and anti-Hes1 antibodies or with control IgG, followed by PCR amplification of the corresponding regions of DNA using specific primers. Analysis of amplified DNA (Figure 7D) showed that immunoprecipitation with anti-Hes1 antibody enriched (compared to control IgG precipitation) sequences that are amplified preferentially by primers flanking N2 box compared to primers flanking N1 box. Amplification of anti-NeuroD immunoprecipitated chromatin did not show any marked enrichment of sequences amplified by primers flanking E9-E11 region. These data show that endogenous HES1 protein in melanoma cells binds to MAP2 promoter region, and suggest that HES1 acts as a dominant factor in regulating MAP2 promoter activity.
###end p 60
###begin title 61
Role of Notch in the regulation of MAP2 promoter activity in melanoma cells
###end title 61
###begin p 62
###xml 481 490 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8A</xref>
###xml 965 974 945 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8B</xref>
###xml 1326 1335 1306 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8C</xref>
###xml 1784 1786 1752 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
To test the effect of Notch1 signaling, a regulator of HES1 expression, on MAP2 promoter activity in melanoma cells, we treated primary and metastatic melanoma cells with gamma-secretase inhibitor, DAPT (which inhibits the cleavage of intracellular domain of Notch1 and hence Notch1 signaling) and/or transfected with HES1shRNA. In primary melanoma cell line WM35, a dose-dependent increase in MAP2 promoter activity was observed with increasing dose of gamma-secretase inhibitor (Figure 8A). Transfection with HES1shRNA or transfection followed by treatment with gamma-secretase inhibitor also caused similar activation of MAP2 promoter. In contrast, treatment with gamma-secretase inhibitor alone was not sufficient to activate MAP2 promoter in metastatic melanoma cell line 451Lu. Transfection with HES1shRNA alone or transfection with HES1 shRNA followed by treatment with gamma-secretase inhibitor was able to upregulate MAP2 promoter activity in these cells (Figure 8B). Treatment with DMSO or transfection with control shRNA did not significantly affect MAP2 promoter activity and were used as controls. Western blot analysis showed that transfection with HES1shRNA alone or treatment of shRNA transfected cells with DAPT decreased the level of HES1 more effectively in primary melanoma cells than in metastatic cells (Figure 8C). Although we did not observe a marked reduction in HES1 levels in shRNA transfected 451Lu cells, there was approximately2-fold increase in MAP2 promoter activity indicating that MAP2 promoter may be sensitive to small changes in HES1 levels. These data suggest that primary melanoma cells are more sensitive to Notch1 inhibition and MAP2 promoter upregulation than metastatic melanoma cells and are consistent with earlier published observations (14).
###end p 62
###begin title 63
DISCUSSION
###end title 63
###begin p 64
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 177 184 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 323 331 323 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 688 695 688 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 802 810 802 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 953 957 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 1030 1034 1030 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
###xml 1024 1029 <span type="species:ncbi:9606">human</span>
Human cutaneous melanoma is known to exhibit molecular plasticity and often express genes characteristic of neural cell lineages (11,28). Our observation that MAP2 is activated in vivo during early stages of melanoma tumor progression, and that NeuroD can upregulate MAP2 promoter activity preferentially in melanoma cells in vitro are consistent with a well-documented tendency of melanoma, a tumor that originates from the neural crest-derived melanocytes, to exhibit neural differentiation. It is now becoming clear that transdifferentiation of melanoma can alter the biology of the tumor and, hence, the clinical outcome in patients. We showed that aggressiveness of primary melanoma in vivo is inversely correlated with MAP2 expression and that overexpression of MAP2 in metastatic melanoma cells in vitro results in cell cycle arrest and growth inhibition (12). In these studies aimed at understanding the mechanisms involved in the activation of MAP2 gene in melanoma cells, we identified the 5' regulatory region of human MAP2 gene and show that MAP2 promoter is regulated by neuronal bHLH factors NeuroD and HES1, and HES1 acts as a dominant regulator of MAP2.
###end p 64
###begin title 65
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MAP2 promoter
###end title 65
###begin p 66
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 329 337 329 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 342 349 342 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1211 1213 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 678 683 <span type="species:ncbi:10090">mouse</span>
###xml 872 875 <span type="species:ncbi:10116">Rat</span>
###xml 880 885 <span type="species:ncbi:9606">human</span>
###xml 1250 1255 <span type="species:ncbi:10090">mouse</span>
###xml 1257 1260 <span type="species:ncbi:10116">rat</span>
###xml 1265 1270 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of genes that encode members of the microtubule-associated proteins, MAP1A, MAP1B and tau, has been investigated (40-44). Interestingly, promoter sequence of MAP2 gene does not share any common features with other MAP genes. Our data show that MAP2 promoter that supports tissue-specific activity both in vitro and in vivo contains multiple bHLH binding sites. We also show that MAP2 promoter is regulated by the neuronal bHLH transcription factors consistent with the wide use of MAP2 expression as marker for neuronal differentiation. Neuron-specific activity of promoters of other MAP genes is less well defined. For example, a 2.4 kb 5' region of mouse MAP1A, which contains two TATA-less promoters and one Sp1 site that regulate the expression of two alternative transcripts, was shown to be active in both neuronal and non-neuronal cells. Rat and human MAP1B promoter sequences, however, contain a consensus element known as 'neuronal motif' (common to several neuronal genes such as GAP43, perinephrin and neurofilament), a Sp1 site, a TCC repeat and a cAMP response element. However, none of these elements appears to be necessary for neuron-specific MAP1B promoter activity (42). Similarly, although promoters for mouse, rat and human tau genes have been isolated, no consensus elements for neuron-specific expression were defined.
###end p 66
###begin p 67
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 1258 1260 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
###xml 482 485 <span type="species:ncbi:10116">rat</span>
###xml 490 495 <span type="species:ncbi:9606">human</span>
###xml 764 767 <span type="species:ncbi:10116">rat</span>
A distinguishing feature of MAP2 promoter is the presence of multiple E boxes, which are known to be recognized by bHLH factors including those that participate in the regulation of cell and tissue-specific gene expression. Presence of E boxes is consistent with neuronal differentiation-specific expression of MAP2. Among the E boxes in the MAP2 promoter, a cluster of three proximal E boxes (E9-E11) are of particular interest because (i) they are strictly conserved among mouse, rat and human, including their relative distance from the transcription start site and spacing between the boxes and (ii) the distal E-box (E9) within this composite element contains a NeuroD-binding sequence CAGATG, identical to that found in well-characterized NeuroD target gene rat glucagon (33). Other known NeuroD target genes that also contain a cluster of three or four E boxes in their proximal promoter regions are insulin and insulinoma-associated antigen 1, Pax6 and sulfonylurea receptor I (20,30,35,45). A comparison of NeuroD-binding E boxes of these genes (including MAP2) showed that NeuroD preferentially binds to the sequence CAN(A/G/T)NTG. Other E-box-like elements (CACNTG) found within this cluster do not appear to be functional with respect to NeuroD (33,45). Mutational analysis of E9, E10 and E11 boxes of MAP2 promoter and gel-shift data presented in this study also support these earlier published observations.
###end p 67
###begin p 68
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 942 944 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 1379 1381 1379 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 780 783 <span type="species:ncbi:10116">rat</span>
###xml 788 793 <span type="species:ncbi:9606">human</span>
###xml 1387 1392 <span type="species:ncbi:9606">human</span>
###xml 1689 1694 <span type="species:ncbi:10090">mouse</span>
###xml 1699 1702 <span type="species:ncbi:10116">rat</span>
###xml 1779 1784 <span type="species:ncbi:10090">mouse</span>
###xml 1793 1796 <span type="species:ncbi:10116">rat</span>
###xml 1845 1850 <span type="species:ncbi:9606">human</span>
Neuronal differentiation is known to be regulated not only by transcriptional activators but also by HES and Id family of repressors (46-48). Among these repressors, the role of HES1 has been extensively investigated. For example, neuronal precursor cells infected with HES1-transducing retrovirus do not differentiate into neurons and fail to activate expression of neuronal markers (49), and Hes1 null mice express both early and late neuronal markers, including MAP2, prematurely (36). HES family repressors can inhibit gene expression either directly by binding (as homodimers) to their cognate-binding elements known as N-boxes (CACNAG) or indirectly by dominant-negative regulation (by forming non-functional heterodimers with transcriptional activators). To our knowledge, rat and human achaete-scute homolog-1 (MASH1), HES1 and E2F1 are the only genes shown to be directly repressed by binding of HES1 to the respective promoters (50-53). In HES1 proximal promoter there are three N-boxes and all three have been shown to bind HES1 and contribute in the autoregulation of HES1 expression (51). E2F1 promoter has a single N-box and binding of HES1 to this element appears to inhibit estrogen and heregulin-mediated upregulation of E2F1 in breast cancer cells (52). On the other hand, hASH1 promoter contains a single HES1-binding class C site with a core sequence CACGCA (50). In human MAP2 promoter, we identified two putative N-boxes, a distal CACAAG (N1) and a proximal CACGAG (N2) box. We showed, by mutational and gel-shift analysis, that the proximal N2 box is involved in HES1-mediated regulation of the promoter activity. Interestingly, these N-boxes are not present in the mouse and rat MAP2 promoters, although a N-box-like CAGGAG element, conserved between the mouse and the rat MAP2, is found at a position similar to that of human MAP2 promoter. However, the role of this N-box-like sequence in the regulation of MAP2 expression in these species remains to be investigated.
###end p 68
###begin p 69
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 498 510 498 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo MAP2</italic>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 1451 1455 1451 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 589 592 <span type="species:ncbi:10116">rat</span>
Our data show that MAP2 gene contains both positive (E boxes) and negative (N-boxes) regulatory elements and suggest that MAP2 expression might be regulated by a balance between positive and negative bHLH factors NeuroD and HES1. This is consistent with the proposal that transition of neuronal precursor cells from proliferation to neurogenesis involves coordinate increase in the pro-neural bHLH factors and a decrease in the activity of HES and Id factors (38). It is tempting to speculate that in vivo MAP2 gene might be regulated by a balance between NeuroD and HES1. For example, in rat insulinoma InR1G9 cell line, insulin gene (a NeuroD target) has been shown to be regulated by the ratio of NeuroD and the transcription repressor Id1 (33). It is therefore possible that variable levels of MAP2 promoter activity in melanoma cell lines may be due to variable ratio of NeuroD and HES1, as both factors are expressed in all melanoma cell lines tested. In this context, it is of interest to note that whereas transfection with increasing amounts of Hes1 plasmid produced a dose-dependent decrease of NeuroD activation of MAP2 promoter, transfection with increasing amount of NeuroD was unable to relieve the repression of the promoter by Hes1. Thus, MAP2 promoter activity seems to be regulated predominantly by HES1 levels. This possibility is also supported by the results of the ChIP assay, which showed that in melanoma cells N-box region of MAP2 gene promoter is occupied by endogenous HES1 protein. Further, reducing endogenous HES1 protein level in melanoma cells using HES1shRNA was also able to increase the basal activity of MAP2 promoter.
###end p 69
###begin p 70
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
###xml 377 379 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 546 548 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 812 814 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 815 817 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 1001 1005 998 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 1081 1085 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
###xml 247 252 <span type="species:ncbi:9606">human</span>
It is also relevant to note that Notch1 signaling, which activates HES1 gene expression, has been shown to be elevated in melanoma cells (54,55). It has also been shown that the activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression and that primary melanoma cells are more sensitive to Notch1 inhibition than metastatic cells (39). Our data, using Notch1 inhibitor, indicate an involvement of Notch1 signaling via HES1 in the regulation of MAP2 gene expression. In agreement with published data (15), we found that primary melanoma cells are more responsive than metastatic cells to inhibition of Notch1 signaling and MAP2 promoter upregulation. These data are also consistent with our earlier findings that MAP2 is expressed more frequently in primary lesions (11,12). Thus, blocking of Notch1 signaling and/or HES1 may be considered as useful therapeutic strategy for melanoma treatment. However, our preliminary findings on induction of endogenous MAP2 gene expression suggest that in addition to regulation by Notch signaling, MAP2 gene is also regulated by epigenetic mechanisms (Nityanand Maddodi, Kumar M. R. Bhat and Vijayasaradhi Setaluri, unpublished data), indicating a tight regulation of this gene during melanoma progression.
###end p 70
###begin p 71
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2</italic>
In summary, our findings on the regulation of neuronal MAP2 promoter gene in melanoma cells are relevant to understanding molecular mechanisms of melanoma progression. A more detailed understanding of the regulation of MAP2 gene transcription in melanoma cells might allow us to design and develop strategies that can activate this gene as a novel therapeutic approach for malignant melanoma.
###end p 71
###begin p 72
We thank Dr Kageyama for providing pCI-Hes1 construct and anti-Hes1 antibody, Dr Jan for providing pcDNA-NeuroD1-FLAG construct, and Dr Suh-Kim for providing NeuroD antibody. We also thank Ms. Smita Ramprakash, Ms. Namratha Sangha and Dr Pichardo for valuable technical help, and Drs Rajendra Kedlaya and Akihiro Ikeda for comments and suggestions. Funding to pay the Open Access publication charges for this article was provided by the Department of Dermatology, University of Wisconsin, Madison, USA.
###end p 72
###begin p 73
###xml 0 31 0 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement.</italic>
Conflict of interest statement. None declared.
###end p 73
###begin title 74
REFERENCES
###end title 74
###begin article-title 75
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro differentiation of embryonic stem cells into glial cells and functional neurons
###end article-title 75
###begin article-title 76
Expression of neuronal markers during NTera2/cloneD1 differentiation by cell aggregation method
###end article-title 76
###begin article-title 77
Suppression of MAP2 in cultured cerebellar macroneurons inhibits minor neurite formation
###end article-title 77
###begin article-title 78
The role of microtubule-associated protein 2c in the reorganization of microtubules and lamellipodia during neurite initiation
###end article-title 78
###begin article-title 79
MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction
###end article-title 79
###begin article-title 80
Microtubule-associated protein 2 (MAP2)-a promising approach to diagnosis of forensic types of hypoxia-ischemia
###end article-title 80
###begin article-title 81
Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors
###end article-title 81
###begin article-title 82
Immunohistochemical characterization of subependymal giant cell astrocytomas
###end article-title 82
###begin article-title 83
Changes in microtubules, microtubule-associated proteins, and intermediate filaments during the differentiation of HL-60 leukemia cells
###end article-title 83
###begin article-title 84
Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel
###end article-title 84
###begin article-title 85
Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma
###end article-title 85
###begin article-title 86
Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma
###end article-title 86
###begin article-title 87
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
###end article-title 87
###begin article-title 88
###xml 71 76 <span type="species:ncbi:9606">human</span>
Activation of Notch1 signaling is required for {beta}-catenin-mediated human primary melanoma progression
###end article-title 88
###begin article-title 89
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression
###end article-title 89
###begin article-title 90
Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF
###end article-title 90
###begin article-title 91
Regulation of microtubule associated protein 2 (MAP2) expression by nerve growth factor in PC12 cells
###end article-title 91
###begin article-title 92
DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2
###end article-title 92
###begin article-title 93
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium
###end article-title 93
###begin article-title 94
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Transactivation of the mouse sulfonylurea receptor I gene by BETA2/NeuroD
###end article-title 94
###begin article-title 95
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Regulation of Hoxc-8 during mouse embryonic development: identification and characterization of critical elements involved in early neural tube expression
###end article-title 95
###begin article-title 96
Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues
###end article-title 96
###begin article-title 97
###xml 24 34 24 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 24 34 <span type="species:ncbi:7227">Drosophila</span>
Target specificities of Drosophila enhancer of split basic helix-loop-helix proteins
###end article-title 97
###begin article-title 98
bHLH transcription factors and mammalian neuronal differentiation
###end article-title 98
###begin article-title 99
###xml 20 25 <span type="species:ncbi:9606">human</span>
Characterization of human Fas gene. Exon/intron organization and promoter region
###end article-title 99
###begin article-title 100
###xml 64 69 <span type="species:ncbi:9606">human</span>
Isolation, sequencing, and functional analysis of the TATA-less human ATPase II promoter
###end article-title 100
###begin article-title 101
###xml 29 34 <span type="species:ncbi:9606">human</span>
Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons
###end article-title 101
###begin article-title 102
Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression
###end article-title 102
###begin article-title 103
###xml 24 29 <span type="species:ncbi:9606">human</span>
Molecular plasticity of human melanoma cells
###end article-title 103
###begin article-title 104
Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor
###end article-title 104
###begin article-title 105
###xml 62 72 <span type="species:ncbi:7227">Drosophila</span>
Hairy function as a DNA-binding helix-loop-helix repressor of Drosophila sensory organ formation
###end article-title 105
###begin article-title 106
Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation
###end article-title 106
###begin article-title 107
Differential regulation of the glucagon and insulin I gene promoters by the basic helix-loop-helix transcription factors E47 and BETA2
###end article-title 107
###begin article-title 108
Orphan nuclear receptor small heterodimer partner, a novel corepressor for a basic helix-loop-helix transcription factor BETA2/NeuroD
###end article-title 108
###begin article-title 109
The PAX6 gene is activated by the basic helix-loop-helix transcription factor NeuroD/BETA2
###end article-title 109
###begin article-title 110
The bHLH gene Hes1 as a repressor of the neuronal commitment of CNS stem cells
###end article-title 110
###begin article-title 111
###xml 63 73 63 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 63 73 <span type="species:ncbi:7227">Drosophila</span>
Two mammalian helix-loop-helix factors structurally related to Drosophila hairy and enhancer of split
###end article-title 111
###begin article-title 112
Basic helix-loop-helix factors in cortical development
###end article-title 112
###begin article-title 113
###xml 71 76 <span type="species:ncbi:9606">human</span>
Activation of Notch1 signaling is required for {beta}-catenin-mediated human primary melanoma progression
###end article-title 113
###begin article-title 114
Characterization of two promoters that regulate alternative transcripts in the microtubule-associated protein (MAP) 1A gene
###end article-title 114
###begin article-title 115
Role for RFX transcription factors in non-neuronal cell-specific inactivation of the microtubule-associated protein MAP1A promoter
###end article-title 115
###begin article-title 116
###xml 67 70 <span type="species:ncbi:10116">rat</span>
Two alternative promoters direct neuron-specific expression of the rat microtubule-associated protein 1B gene
###end article-title 116
###begin article-title 117
Structural analysis of the proximal region of the microtubule-associated protein 1B promoter
###end article-title 117
###begin article-title 118
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Transcriptional regulation of the mouse microtubule-associated protein tau
###end article-title 118
###begin article-title 119
NeuroD1/E47 regulates the E-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system
###end article-title 119
###begin article-title 120
Regulation of mammalian neural development by helix-loop-helix transcription factors
###end article-title 120
###begin article-title 121
Basic helix-loop-helix genes in neural development
###end article-title 121
###begin article-title 122
Inhibition of BETA2/NeuroD by Id2
###end article-title 122
###begin article-title 123
Persistent expression of helix-loop-helix factor HES-1 prevents mammalian neural differentiation in the central nervous system
###end article-title 123
###begin article-title 124
###xml 20 30 20 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 20 30 <span type="species:ncbi:7227">Drosophila</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression
###end article-title 124
###begin article-title 125
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
Structure, chromosomal locus, and promoter analysis of the gene encoding the mouse helix-loop-helix factor HES-1. Negative autoregulation through the multiple N box elements
###end article-title 125
###begin article-title 126
HES-1 inhibits 17-estradiol and heregulin-1-mediated upregulation of E2F-1
###end article-title 126
###begin article-title 127
Activating the PARP-1 sensor component of the Groucho/TLE1 corepressor complex mediates a CaMKinase II[delta]-dependent neurogenic gene activation pathway
###end article-title 127
###begin article-title 128
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents
###end article-title 128
###begin article-title 129
###xml 29 34 <span type="species:ncbi:9606">human</span>
Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination
###end article-title 129
###begin title 130
Figures and Tables
###end title 130
###begin p 131
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 342 343 342 343 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 345 350 <span type="species:ncbi:10090">Mouse</span>
###xml 355 358 <span type="species:ncbi:10116">rat</span>
###xml 402 407 <span type="species:ncbi:9606">human</span>
(A) Schematic diagram of the 3.3 kb human MAP2 genomic DNA fragment consisting 5' regulatory region, the first exon and partial sequence of the first intron, and different promoter constructs used in this study. The relative location (not drawn to scale) of putative E- and N-boxes, and the transcription start site (arrow at +1) are shown. (B) Mouse and rat genomic sequences homologous to the 3.3 kb human MAP2 promoter region were retrieved from GenBank database by BLAST search, conserved E- and N-boxes region was aligned using CLUSTALW sequence alignment program and shown by shading using Boxshade program. Dashes show gaps in the sequences. Conserved E boxes and N2 box sequences are highlighted.
###end p 131
###begin p 132
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 71 72 71 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 94 95 94 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 267 274 267 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 307 314 307 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 126 129 <span type="species:ncbi:10116">rat</span>
###xml 646 651 <span type="species:ncbi:9606">Human</span>
###xml 1139 1144 <span type="species:ncbi:9606">human</span>
###xml 1189 1194 <span type="species:ncbi:9606">human</span>
MAP2 promoter activity: activity of MAP2 promoter in PC12 (A), NT2/D1 (B) and melanoma cells (C). (A) Control and NGF-treated rat PC12 cells and HeLa cells were transfected in triplicates in 24-well plates with the indicated MAP2 promoter-luciferase plasmids and the Renilla luciferase plasmid. Firefly and Renilla luciferase activities were measured using Dual Luciferase Reporter Assay System (Promega). Data from a representative of at least three experiments are shown as fold induction compared to the activity of promoter without NGF. Panels on right in (A) show immunostaining of control and NGF-treated PC12 cells with anti-MAP2 mAb. (B) Human teratocarcinoma cell line NT2/D1 (grown long term in medium containing serum) and HeLa cells were transfected with the indicated MAP2 promoter constructs and luciferase activity was measured as described above. Data are shown as RLA (RLA = 1). Error bars: means +/- SEM. Inset in (B) shows RT-PCR analysis of MAP2 mRNA expression in HeLa and NT2/D1 cells. Total RNA (100 ng) was used to perform RT-PCR (OneStep RT-PCR kit; Qiagen) using primers that amplify a 709 bp fragment that spans human MAP2 exons 3-9. (C) Activity of phMAP2-2 in human primary and metastatic melanoma cell lines. Luciferase activity was measured and data (means +/- SEM) are shown as RLA.
###end p 132
###begin p 133
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 39 40 39 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 450 451 444 445 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 580 585 <span type="species:ncbi:10090">mouse</span>
###xml 747 752 <span type="species:ncbi:10090">mouse</span>
Human MAP2 promoter activity in vivo. (A) Whole-mount in situ staining of 11.5-day-old pHSF-6/MAP2-1/lacZ promoter transgenic embryo with X-gal for beta-galactosidase gene expression. The beta-galactosidase expression is seen mostly in the developing central nervous system. TV, telencephalic vesicle; VM, ventral mesencephalon; I, isthmus (midbrain-hind brain junction) and rhombic lip; and NT, neural tube. Areas of the head and the tail shown in (B) are indicated by red colored squares. (B) Paraffin sections of head region and tail regions of 11.5-day-old littermate control mouse embryos were stained with anti-MAP2ab mAb M13 (Zymed) (right panels) or control IgG (left panels) using citrate buffer antigen retrieval method followed by anti-mouse IgG-HRP and AEC detection method. Endogenous MAP2ab protein expression is seen in regions of the embryo that correspond to the region of X-gal staining. Upper panels: low magnification; lower panels: high magnification of the areas indicated by red squares in the upper panels.
###end p 133
###begin p 134
###xml 54 55 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 406 414 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 447 448 445 446 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 509 511 507 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 903 909 <span type="species:ncbi:9986">rabbit</span>
###xml 926 932 <span type="species:ncbi:9986">rabbit</span>
Role of NeuroD/BETA2 in regulation of MAP2 promoter. (A) HeLa cells and metastatic melanoma cells c22a were transfected with indicated MAP2 promoter-reporter plasmids and either 25 or 100 ng of NeuroD expression plasmid pcDNA3-NeuroD1-FLAG or 100 ng of pcDNA3. Equal amount of total DNA was used in all transfection. Luciferase activities were measured and RLA was calculated as described in the legend to Figure 1. Data shown are means +/- SEM. (B) Electrophoretic mobility shift analysis of E-box sequence. 32P-labeled double-stranded 22mer oligonucleotides with core sequence of E9 box CAGATG (see Materials and Methods) were incubated with nuclear extract (5-10 mug protein) of c22a metastatic melanoma cells transfected with pNeuroD either alone or in the presence of 5-50 M excess cold E9, E10 or mutant E9 oligonucleotides. Lanes 8 and 9 show mobility shift pattern after the addition of control rabbit IgG (lane 8) or rabbit anti-NeuroD antibody (lane 9) to the E8 oligonucleotide-protein complexes.
###end p 134
###begin p 135
###xml 46 47 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 286 287 286 287 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 400 401 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 419 421 417 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t-</italic>
###xml 427 428 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 440 441 438 439 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 774 782 770 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
Indirect activation MAP2 promoter by NeuroD. (A) HeLa cells and metastatic melanoma cells c22a were co-transfected with phMAP2-3 promoter-reporter plasmid lacking the E9 box and NeuroD expression plasmid pcDNA3-NeuroD-FLAG (pNeuroD) (25 and 100 ng) or 100 ng of control pcDNA3 vector. (B) Effect of mutation of the core E9 box sequence (CAGATG-->ACGAGT) on MAP2 promoter activity. Asterisk indicates P-value (Student's t-test, P < 0.001). (C) Dose-dependent activation of mutE9- phMAP2-2 promoter by NeuroD. c22a melanoma cells were co-transfected with mutE9 phMAP2-3 and increasing amount of pNeuroD plasmid. Equal amounts of total DNA were used in all transfections. Luciferase activities were measured and RLA (means +/- SEM) was calculated as described in the legend to Figure 1.
###end p 135
###begin p 136
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 491 492 487 488 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 731 733 727 729 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AC</underline>
###xml 735 737 731 733 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GA</underline>
###xml 747 749 743 745 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GC</underline>
###xml 751 753 747 749 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CC</underline>
###xml 886 887 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 930 931 926 927 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1343 1344 1338 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1355 1356 1350 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1399 1400 1394 1395 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1928 1929 1919 1920 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1981 1983 1972 1974 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 73 78 <span type="species:ncbi:9606">Human</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 2280 2286 <span type="species:ncbi:9986">rabbit</span>
HES1 (hairy and enhancer of split) represses MAP2 promoter activity. (A) Human metastatic melanoma cells were transfected with 2.2 kb phMAP2-2 promoter and increasing amounts (0.1, 0.3 and 0.6 mug) of mouse Hes1 expression plasmid pCI-Hes1 or 0.6 mug the empty vector pcDNA3. Forty-eight hours after transfection luciferase activities were measured. RLA were calculated and MAP2 promoter activity in Hes1 expressing cells is shown as percent (means +/- SEM) of pcDNA3 co-transfected cells. (B) Mutational analysis of the role of N-boxes in repression of MAP2 promoter by Hes1. Metastatic melanoma cells were transfected with wild-type (wt) and N-box mutated (mutated nucleotides shown underlined) phMAP2-2 promoter plasmids mutN1 (ACCAGA), mutN2 (GCCGCC) and mutN1N2 and luciferase activity in cells transfected with mutant plasmids is shown as percent of wild-type transfected cells (*P < 0.05 compared with wt; one-way ANOVA). (C) Metastatic melanoma cells were transfected with wt and N-box mutant plasmids together with 1.5 mug empty vector pcDNA or pCI-Hes1 plasmid and luciferase activities in cell lysates was measured 48 h after the transfection. Repression of the wild-type and N-box mutant promoter activity by Hes1 is shown as percent activity of wild-type and the mutant plasmids in cells transfected with the pcDNA empty vector (*P < 0.05; **P < 0.01 compared with wt; one-way ANOVA). (D) Repression of the phMAP2-4 (-263/+30) promoter by Hes1. Melanoma cells in 24-well plate were transfected, in triplicates, with 0.6 mug phMAP2-4 plasmid and 0.6 mug of empty vector pcDNA or indicated amounts of pCI-Hes1 plasmid. After 48 h transfection, cells were lysed and RLA was determined. MAP2 promoter activity in the presence of Hes1 is shown as percent of empty vector transfected cells. Equal amount of total DNA was used in all transfection. Data (mean +/- SEM) shown are representative of least three experiments. (E) Electrophoretic mobility shift analysis of N-box. 32P-labeled N2 box double-stranded oligonucleotides were incubated with nuclear extract (5-10 mug protein) of pCI-Hes1 transfected c22a metastatic melanoma cell either alone or in the presence of 5-50 M excess cold N1, N2 or mutant N2 box oligonucleotides or a polyclonal Hes1 antibody or a control rabbit IgG. Left arrow indicates the specific N2 box DNA-protein complex and the right arrow indicates the Hes1 supershifted complexes. Asterisks indicate non-specific complexes.
###end p 136
###begin p 137
###xml 57 58 57 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 347 348 346 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 983 984 979 980 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1658 1659 1650 1651 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1401 1405 <span type="species:ncbi:9925">goat</span>
###xml 1411 1416 <span type="species:ncbi:10090">mouse</span>
###xml 1447 1452 <span type="species:ncbi:10090">mouse</span>
HES1 is a dominant repressor of MAP2 promoter activity. (A) Melanoma cells were transfected with phMAP2-2 promoter-luciferase plasmid alone, or with Hes1 expression plasmid pCI-Hes1 or NeuroD expression plasmid pcDNA3-NeuroD-FLAG. In addition, 0.1 and 0.3 mug of Hes1 expression plasmid pCI-Hes1 was included in cells co-transfected with NeuroD. (B) c22a melanoma cells were transfected with phMAP2-2 promoter-luciferase plasmid alone, or with Hes1 expression plasmid pCI-Hes1 or NeuroD expression plasmid pcDNA3-NeuroD-FLAG. Cells in additional wells transfected with pCI-Hes1 also received 0.1 or 0.3 mug of pNeuroD plasmid. Equal amount of total DNA was used in all transfection. Luciferase activities were measured and the promoter activity in cells co-transfected with either pcDNA3-NeuroD or pCI-Hes1 alone or with increasing amounts of pCI-Hes1 or pcDNA3-NeuroD1, respectively, is shown as percentage (means +/- SEM) of activity in cells transfected with phMAP2-2 and pcDNA. (C) Expression of NeuroD and HES1 in melanocytes and melanoma cells. Western blot analysis of NeuroD expression in control and pcDNA3-Neuro-FLAG plasmid transfected COS cells, neonatal foreskin melanocytes (NMC), primary melanoma cell line WM75 and various metastatic melanoma cell lines. Seventy-five micrograms of detergent soluble total cellular proteins were separated by SDS-PAGE and immunoblotted with polyclonal goat anti-mouse NeuroD (upper panel) and anti-mouse Hes1 antibody (lower panel), followed by HRP-conjugated secondary antibody. Protein bands were detected by chemiluminescence. Western blotting for alpha-tubulin is shown as a control for protein loading. (D) Chromatin immunoprecipitation assay. Sheared chromatin from melanoma cells was immunoprecipitated (IP) with appropriate antibody (anti-HES1, anti-NeuroD or control IgG) and antibody bound DNA was isolated according to the manufacturer's protocol (Active Motif, Carlsbad, CA). Immunoprecipitated DNA was used as template in PCR using N1 and N2 primer (for HES1), E9-E11 primer (for NeuroD). GAPDH primers were used as control.
###end p 137
###begin p 138
###xml 106 107 106 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 147 148 147 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 519 527 512 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 709 710 702 703 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Notch1 signaling is involved in MAP2 promoter regulation in melanoma cells. Primary melanoma cells, WM35 (A) and metastatic melanoma cells, 451Lu (B) were either pre-treated with 1 or 2 muM gamma-secretase inhibitor (DAPT) or transfected with 0.6 mug of HES1shRNA and then treated with 2 muM DAPT. After 24 h, the cells were transfected with phMAP2-2 luciferase-promoter construct. Cells were lysed and luciferase activity was measured 48 h after promoter transfection. RLA was calculated as described in the legend to Figure 2. Data are shown as percent activity of control DMSO-treated cells or control shRNA transfected cells, and are from a representative of two individual experiments with triplicates. (C) Western blotting analysis of primary (WM35) and metastatic (451Lu) melanoma cells transfected with HES1shRNA alone or in combination with the treatment of DAPT, show decreased level of endogenous HES1 protein. Western blotting of beta-actin is shown as loading control.
###end p 138

